1. Home
  2. VTEX vs ENGN Comparison

VTEX vs ENGN Comparison

Compare VTEX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VTEX

VTEX

VTEX

HOLD

Current Price

$3.87

Market Cap

561.5M

Sector

Technology

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$7.18

Market Cap

647.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTEX
ENGN
Founded
1999
1999
Country
Cayman Islands
Canada
Employees
N/A
82
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
561.5M
647.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
VTEX
ENGN
Price
$3.87
$7.18
Analyst Decision
Buy
Buy
Analyst Count
6
5
Target Price
$5.97
$21.00
AVG Volume (30 Days)
1.2M
501.8K
Earning Date
05-05-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.64
N/A
Revenue Next Year
$10.57
N/A
P/E Ratio
$43.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.84
$2.66
52 Week High
$6.82
$12.25

Technical Indicators

Market Signals
Indicator
VTEX
ENGN
Relative Strength Index (RSI) 60.51 33.89
Support Level $3.68 $6.03
Resistance Level $4.23 $7.33
Average True Range (ATR) 0.20 0.66
MACD 0.03 -0.18
Stochastic Oscillator 66.20 16.04

Price Performance

Historical Comparison
VTEX
ENGN

About VTEX VTEX

Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: